Local radiotherapy increases the level of autoantibodies to ribosomal P0 protein but not to heat shock proteins, extracellular matrix molecules and EGFR/ErbB2 receptors in prostate cancer patients

Ingrosso,Gianluca; Fantini,Massimo; Nardi,Alessandra; Benvenuto,Monica; Sacchetti,Pamela; Masuelli,Laura; Ponti,Elisabetta; Frajese,Giovanni  Vanni; Lista,Florigio; Schillaci,Orazio; Santoni,Riccardo; Modesti,Andrea; Bei,Roberto

doi:10.3892/or.2012.2197

Local radiotherapy increases the level of autoantibodies to ribosomal P0 protein but not to heat shock proteins, extracellular matrix molecules and EGFR/ErbB2 receptors in prostate cancer patients

Authors:
- Gianluca Ingrosso
- Massimo Fantini
- Alessandra Nardi
- Monica Benvenuto
- Pamela Sacchetti
- Laura Masuelli
- Elisabetta Ponti
- Giovanni Vanni Frajese
- Florigio Lista
- Orazio Schillaci
- Riccardo Santoni
- Andrea Modesti
- Roberto Bei
View Affiliations

Affiliations: Department of Diagnostic Imaging, Molecular Imaging, Interventional Radiology and Radiotherapy, University of Rome ‘Tor Vergata’, Rome, Italy, Department of Clinical Sciences and Translational Medicine, University of Rome ‘Tor Vergata’, Rome, Italy, Department of Mathematics, University of Rome ‘Tor Vergata’, Rome, Italy, Department of Experimental Medicine, University of Rome ‘Sapienza’, Rome, Italy, Faculty of Motor and Adaptive Sciences, University of Cassino, Cassino, Italy, Laboratory of Molecular Biology, Army Medical Research Centre, Rome, Italy
Published online on: December 18, 2012 https://doi.org/10.3892/or.2012.2197
Pages: 1167-1174

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostate cancer is a common cancer among men in developed countries. Although hormonotherapy and radiotherapy (RT) represent valid therapies for prostate cancer treatment, novel immunological approaches have been explored. The development of clinical trials employing cancer vaccines has indicated that immune response to tumor antigens can be boosted and that vaccine administration can improve patient survival. Immune response to tumor antigens could also be enhanced after standard therapies. In the present study, we determined the occurrence of antibodies to extracellular matrix (ECM) molecules, heat shock protein (HSP), ribosomal P0 protein, EGFR, ErbB2 and prostate-specific antigen (PSA) in 35 prostate cancer patients prior to and following local RT and hormonotherapy. We demonstrated that immunity to P0, ECM molecules [collagens (C) CI, CIII, CV, fibronectin (FN) and laminin (LM)] and to HSP90 was associated with malignancy in untreated patients. None of the patient sera showed antibodies to EGFR, while 2 and 1 patients showed reactivity to ErbB2 and PSA, respectively. We also demonstrated that 8 months after therapy the IgG serum levels to CI, CIII, FN and HSP90 significantly decreased. Conversely, the level of P0 autoantibodies increased after therapy in 10 patients. Five of the 10 patients with increased levels of P0 autoantibodies were treated with RT plus hormonotherapy. Treatment of patients did not change the levels of antibodies against EGFR, ErbB2 and PSA. Our results indicated that the modification of antibody level to self molecules after standard treatment of prostate cancer patients is influenced by the type of antigen. Ribosomal P0 protein appears to be a high immunogenic antigen and its immunogenicity increases following RT. In addition, 10 patients with increased levels of autoantibodies to P0 showed PSA mean levels lower than the remaining 25 patients at 18 months. This study may contribute to a better understanding of the immunobiological behavior of prostate cancer patients following standard treatment.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	D'Amico AV: Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer. Urology. 60(Suppl 1): 32–37. 2002. View Article : Google Scholar
3	Palumbo C, Bei R, Procopio A and Modesti A: Molecular targets and targeted therapies for malignant mesothelioma. Curr Med Chem. 15:855–867. 2008. View Article : Google Scholar : PubMed/NCBI
4	McNeel DG, Nguyen LD, Storer BE, Vessella R, Lange PH and Disis ML: Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer. J Urol. 164:1825–1829. 2000. View Article : Google Scholar : PubMed/NCBI
5	Olson BM and McNeel DG: Antibody and T-cell responses specific for the androgen receptor in patients with prostate cancer. Prostate. 67:1729–1739. 2007. View Article : Google Scholar : PubMed/NCBI
6	Ronquist KG, Carlsson L, Ronquist G, Nilsson S and Larsson A: Prostasome-derived proteins capable of eliciting an immune response in prostate cancer patients. Int J Cancer. 119:847–853. 2006. View Article : Google Scholar : PubMed/NCBI
7	Massoner P, Lueking A, Goehler H, et al: Serum-autoantibodies for discovery of prostate cancer specific biomarkers. Prostate. 72:427–436. 2012. View Article : Google Scholar : PubMed/NCBI
8	Agarwal N, Padmanabh S and Vogelzang NJ: Development of novel immune interventions for prostate cancer. Clin Genitourin Cancer. 10:84–92. 2012. View Article : Google Scholar : PubMed/NCBI
9	Mercader M, Bodner BK, Moser MT, et al: T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA. 98:14565–14570. 2001. View Article : Google Scholar : PubMed/NCBI
10	Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A and Thompson TC: Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res. 60:5857–5861. 2000.PubMed/NCBI
11	Vesalainen S, Lipponen P, Talja M and Syrjänen K: Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer. 30A:1797–1803. 1994. View Article : Google Scholar
12	Gulley JL and Drake CG: Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin Cancer Res. 17:3884–3891. 2011. View Article : Google Scholar : PubMed/NCBI
13	Nesslinger NJ, Ng A, Tsang KY, Ferrara T, Schlom J, Gulley JL and Nelson BH: A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients. Clin Cancer Res. 16:4046–4056. 2010. View Article : Google Scholar
14	Becker JT, Olson BM, Johnson LE, Davies JG, Dunphy EJ and McNeel DG: DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother. 33:639–647. 2010. View Article : Google Scholar : PubMed/NCBI
15	Kantoff PW, Schuetz TJ, Blumenstein BA, et al: Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 28:1099–1105. 2010. View Article : Google Scholar
16	Nesslinger NJ, Sahota RA, Stone B, et al: Standard treatments induce antigen-specific immune responses in prostate cancer. Clin Cancer Res. 13:1493–1502. 2007. View Article : Google Scholar : PubMed/NCBI
17	Koukourakis MI: Radiation damage and radioprotectants: new concepts in the era of molecular medicine. Br J Radiol. 85:313–330. 2012. View Article : Google Scholar : PubMed/NCBI
18	Yarnold J and Brotons MC: Pathogenetic mechanisms in radiation fibrosis. Radiother Oncol. 97:149–161. 2010. View Article : Google Scholar : PubMed/NCBI
19	Mothersill CE, Moriarty MJ and Seymour CB: Radiotherapy and the potential exploitation of bystander effects. Int J Radiat Oncol Biol Phys. 58:575–579. 2004. View Article : Google Scholar : PubMed/NCBI
20	Marzocchella L, Fantini M, Benvenuto M, Masuelli L, Tresoldi I, Modesti A and Bei R: Dietary flavonoids: molecular mechanisms of action as anti-inflammatory agents. Recent Pat Inflamm Allergy Drug Discov. 5:200–220. 2011. View Article : Google Scholar : PubMed/NCBI
21	Schmid TE and Multhoff G: Radiation-induced stress proteins-the role of heat shock proteins (HSP) in anti-tumor responses. Curr Med Chem. 19:1765–1770. 2012. View Article : Google Scholar : PubMed/NCBI
22	Boerma M, van der Wees CG, Vrieling H, et al: Microarray analysis of gene expression profiles of cardiac myocytes and fibroblasts after mechanical stress, ionising or ultraviolet radiation. BMC Genomics. 6:62005. View Article : Google Scholar : PubMed/NCBI
23	Niehoff P, Wiltfang J, Springer IN, Weppner N, Kimmig B and Acil Y: Increased excretion of collagen crosslinks in irradiated patients indicates destruction of collagen. Int J Radiat Biol. 82:503–509. 2006. View Article : Google Scholar : PubMed/NCBI
24	Ehrhart EJ, Gillette EL and Barcellos-Hoff MH: Immunohistochemical evidence of rapid extracellular matrix remodeling after iron-particle irradiation of mouse mammary gland. Radiat Res. 145:157–162. 1996. View Article : Google Scholar
25	Harriss W, Bezak E, Yeoh E and Hermans M: Measurement of reoxygenation during fractionated radiotherapy in head and neck squamous cell carcinoma xenografts. Australas Phys Eng Sci Med. 33:251–263. 2010. View Article : Google Scholar : PubMed/NCBI
26	Magagnin MG, Sergeant K, van den Beucken T, et al: Proteomic analysis of gene expression following hypoxia and reoxygenation reveals proteins involved in the recovery from endoplasmic reticulum and oxidative stress. Radiother Oncol. 83:340–345. 2007. View Article : Google Scholar : PubMed/NCBI
27	Izzi V, Masuelli L, Tresoldi I, Foti C, Modesti A and Bei R: Immunity and malignant mesothelioma: from mesothelial cell damage to tumor development and immune response-based therapies. Cancer Lett. 322:18–34. 2012. View Article : Google Scholar : PubMed/NCBI
28	Fernandez-Madrid F, Karvonen RL, Kraut MJ, Czelusniak B and Ager JW: Autoimmunity to collagen in human lung cancer. Cancer Res. 56:121–126. 1996.PubMed/NCBI
29	Kalluri R, Petrides S, Wilson CB, et al: Anti-alpha1(IV) collagen autoantibodies associated with lung adenocarcinoma presenting as the Goodpasture syndrome. Ann Intern Med. 124:651–653. 1996. View Article : Google Scholar : PubMed/NCBI
30	Tong YQ, Zhang ZJ, Liu B, et al: Autoantibodies as potential biomarkers for nasopharyngeal carcinoma. Proteomics. 8:3185–3193. 2008. View Article : Google Scholar : PubMed/NCBI
31	Young AL, Bailey EE, Colaço SM, Engler DE and Grossman ME: Anti-laminin-332 mucous membrane pemphigoid associated with recurrent metastatic prostate carcinoma: hypothesis for a paraneoplastic phenomenon. Eur J Dermatol. 21:401–404. 2011.
32	Bei R, Masuelli L, Palumbo C, Tresoldi I, Scardino A and Modesti A: Long-lasting tissue inflammatory processes trigger autoimmune responses to extracellular matrix molecules. Int Rev Immunol. 27:137–175. 2008. View Article : Google Scholar : PubMed/NCBI
33	Bei R, Mentuccia D, Trono P, et al: Immunity to extracellular matrix antigens is associated with ultrastructural alterations of the stroma and stratified epithelium basement membrane in the skin of Hashimotos thyroiditis patients. Int J Immunopathol Pharmacol. 19:661–674. 2006.
34	Masuelli L, Pompa G, Fabrizi M, et al: Patients with periimplantitis, unlike those with a healthy peri-implant microenvironment, display antibodies to more than one heat shock protein (HSP 27, HSP 65 and HSP 90) linear epitope. Eur J Inflammation. 9:257–268. 2011.
35	Bei R, Masuelli L, Palumbo C, Modesti M and Modesti A: A common repertoire of autoantibodies is shared by cancer and autoimmune disease patients: inflammation in their induction and impact on tumor growth. Cancer Lett. 281:8–23. 2009. View Article : Google Scholar : PubMed/NCBI
36	Jego G, Hazoumé A, Seigneuric R and Garrido C: Targeting heat shock proteins in cancer. Cancer Lett. Nov 13–2010.(Epub ahead of print).
37	Suzuki H, Sugimura H and Hashimoto K: Overexpression of heat shock protein 27 is associated with good prognosis in the patient with oral squamous cell carcinoma. Br J Oral Maxillofac Surg. 45:123–129. 2007. View Article : Google Scholar : PubMed/NCBI
38	Wahl MC and Moller W: Structure and function of the acidic ribosomal stalk proteins. Curr Protein Pept Sci. 3:93–106. 2002. View Article : Google Scholar : PubMed/NCBI
39	Koscec M, Koren E, Wolfson-Reichlin M, et al: Autoantibodies to ribosomal P proteins penetrate into live hepatocytes and cause cellular dysfunction in culture. J Immunol. 159:2033–2041. 1997.PubMed/NCBI
40	Mahler M, Kessenbrock K, Szmyrka M, et al: International multicenter evaluation of autoantibodies to ribosomal P proteins. Clin Vaccine Immunol. 13:77–83. 2006. View Article : Google Scholar : PubMed/NCBI
41	Gerli R and Caponi L: Anti-ribosomal P protein antibodies. Autoimmunity. 38:85–92. 2005. View Article : Google Scholar : PubMed/NCBI
42	Bei R, Masuelli L, Trono P, et al: The ribosomal P0 protein induces a spontaneous immune response in patients with head and neck advanced stage carcinoma that is not dependent on its overexpression in carcinomas. Int J Oncol. 31:1301–1308. 2007.PubMed/NCBI
43	Marzocchella L, Sini V, Buonomo O, et al: Spontaneous immunogenicity of ribosomal P0 protein in patients with benign and malignant breast lesions and delay of mammary tumor growth in P0-vaccinated mice. Cancer Sci. 102:509–515. 2011. View Article : Google Scholar : PubMed/NCBI
44	Sun KH, Tang SJ, Lin ML, Wang YS, Sun GH and Liu WT: Monoclonal antibodies against human ribosomal P proteins penetrate into living cells and cause apoptosis of Jurkat T cells in culture. Rheumatology. 40:750–756. 2001. View Article : Google Scholar : PubMed/NCBI
45	Bei R, Masuelli L, Moriconi E, Visco V, Moretti A, Kraus MH and Muraro R: Immune responses to all ErbB family receptors detectable in serum of cancer patients. Oncogene. 18:1267–1275. 1999. View Article : Google Scholar : PubMed/NCBI
46	Masuelli L, Focaccetti C, Cereda V, et al: Gene-specific inhibition of breast carcinoma in BALB-neuT mice by active immunization with rat Neu or human ErbB receptors. Int J Oncol. 30:381–392. 2007.PubMed/NCBI
47	Bei R, Pompa G, Vitolo D, et al: Co-localization of multiple ErbB receptors in stratified epithelium of oral squamous cell carcinoma. J Pathol. 195:343–348. 2001. View Article : Google Scholar : PubMed/NCBI
48	Masuelli L, Marzocchella L, Focaccetti C, et al: Local delivery of recombinant vaccinia virus encoding for neu counteracts growth of mammary tumors more efficiently than systemic delivery in neu transgenic mice. Cancer Immunol Immunother. 59:1247–1258. 2010. View Article : Google Scholar : PubMed/NCBI
49	Masuelli L, Marzocchella L, Quaranta A, et al: Apigenin induces apoptosis and impairs head and neck carcinomas EGFR/ErbB2 signaling. Front Biosci. 16:1060–1068. 2011. View Article : Google Scholar : PubMed/NCBI
50	Masuelli L, Bei R, Sacchetti P, et al: Beta-catenin accumulates in intercalated disks of hypertrophic cardiomyopathic hearts. Cardiovasc Res. 60:376–387. 2003. View Article : Google Scholar : PubMed/NCBI
51	Masuelli L, Marzocchella L, Focaccetti C, et al: Resveratrol and diallyl disulfide enhance curcumin-induced sarcoma cell apoptosis. Front Biosci. 17:498–508. 2012. View Article : Google Scholar : PubMed/NCBI
52	Masuelli L, Budillon A, Marzocchella L, et al: Caveolin-1 overexpression is associated with simultaneous abnormal expression of the E-cadherin/α-β catenins complex and multiple ErbB receptors and with lymph nodes metastasis in head and neck squamous cell carcinomas. J Cell Physiol. 227:3344–3353. 2012.PubMed/NCBI
53	Bei R, Budillon A, Reale MG, et al: Cryptic epitopes on alpha-fetoprotein induce spontaneous immune responses in hepatocellular carcinoma, liver cirrhosis, and chronic hepatitis patients. Cancer Res. 59:5471–5474. 1999.
54	Turriziani M, Fantini M, Benvenuto M, et al: Carcinoembryonic antigen (CEA)-based cancer vaccines: recent patents and antitumor effects from experimental models to clinical trials. Recent Pat Anticancer Drug Discov. 7:265–296. 2012. View Article : Google Scholar
55	Bei R and Mizejewski GJ: Alpha fetoprotein is more than a hepatocellular cancer biomarker: from spontaneous immune response in cancer patients to the development of an AFP-based cancer vaccine. Curr Mol Med. 11:564–581. 2011. View Article : Google Scholar : PubMed/NCBI
56	Bei R, Budillon A, Masuelli L, et al: Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients. J Pathol. 204:317–325. 2004. View Article : Google Scholar : PubMed/NCBI
57	Scardino A, Alimandi M, Correale P, et al: A polyepitope DNA vaccine targeted to Her-2/ErbB-2 elicits a broad range of human and murine CTL effectors to protect against tumor challenge. Cancer Res. 67:7028–7036. 2007. View Article : Google Scholar : PubMed/NCBI
58	Larsson A, Ronquist G, Wülfing C, et al: Antiprostasome antibodies: possible serum markers for prostate cancer metastasizing liability. Urol Oncol. 24:195–200. 2006. View Article : Google Scholar : PubMed/NCBI
59	Hurwitz MD, Kaur P, Nagaraja GM, Bausero MA, Manola J and Asea A: Radiation therapy induces circulating serum Hsp72 in patients with prostate cancer. Radiother Oncol. 95:350–358. 2010. View Article : Google Scholar : PubMed/NCBI
60	Knobloch V and Plundrová D: Immunocomplexes in pregnancy. II. Phagocytosed complexes in the peripheral blood. Cesk Gynekol. 51:611–616. 1986.(In Czech).
61	Kossenkov AV, Vachani A, Chang C, et al: Resection of non-small cell lung cancers reverses tumor-induced gene expression changes in the peripheral immune system. Clin Cancer Res. 17:5867–5877. 2011. View Article : Google Scholar : PubMed/NCBI
62	Plotz PH: The autoantibody repertoire: searching for order. Nat Rev Immunol. 3:73–78. 2003. View Article : Google Scholar : PubMed/NCBI